Particular clinical features of the underlying non-vascular forms of AMD, such as thick or thin retinae, thicker sub-retinal tissue, atrophy, or the presence of fibrotic scarring, are all associated with worse baseline VA3 in clinical trials of VEGF inhibitors. The gene discussed is VEGFA; the disease is age-related macular degeneration.